Blog › GLP-1 RC-S vs GLP-1 RC-T
Comparison

GLP-1 RC-S vs GLP-1 RC-T: Key Differences Explained

January 13, 2026 · 10 min read

GLP-1 RC-S and GLP-1 RC-T are two of the most studied peptides in metabolic research. Both target incretin pathways, but they differ fundamentally in receptor selectivity, molecular structure, and mechanism of action. This article breaks down the science behind each compound and what the published literature reveals. For the brand-name framing question (“is Ozempic a peptide?”) see our explainer on semaglutide and the wider GLP-1 family; for the triple-agonist case (GIP / GLP-1 / glucagon), see our UK retatrutide guide.

At a Glance

PropertyGLP-1 RC-SGLP-1 RC-T
Receptor TargetsGLP-1 receptor (single agonist)GLP-1 + GIP receptors (dual agonist)
Amino Acids31 amino acids39 amino acids
Half-Life~7 days~5 days
Molecular Weight~4,114 Da~4,810 Da
AdministrationOnce weeklyOnce weekly
Fatty Acid ModificationC18 fatty di-acidC20 fatty di-acid
Primary Research FocusMetabolic regulation, appetite signallingMetabolic regulation, dual-incretin signalling

Mechanism of Action

GLP-1 RC-S: GLP-1 Receptor Agonist

GLP-1 RC-S is a modified analogue of human glucagon-like peptide-1 (GLP-1). It binds selectively to the GLP-1 receptor, which is expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and the cardiovascular system.

Its key modifications include an amino acid substitution at position 8 (Aib for Ala) that confers resistance to DPP-4 enzymatic degradation, and a C18 fatty di-acid side chain attached via a linker at Lys26 that promotes albumin binding. This albumin binding extends the half-life to approximately 7 days, enabling once-weekly dosing.

At the cellular level, GLP-1 receptor activation stimulates cyclic AMP (cAMP) production, which enhances glucose-dependent insulin secretion, suppresses glucagon release, and activates satiety centers in the hypothalamus.

GLP-1 RC-T: Dual GIP/GLP-1 Receptor Agonist

GLP-1 RC-T is the first peptide to combine agonist activity at both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. Its 39 amino acid sequence is based on the native GIP sequence with modifications that confer GLP-1 receptor cross-reactivity.

The rationale for dual agonism is based on the complementary roles these incretins play. GIP and GLP-1 are both secreted from the gut after food intake and together account for 50-70% of postprandial insulin secretion. By activating both pathways simultaneously, glp-1-rc-t engages a broader set of metabolic mechanisms than either incretin alone.

Key distinction: GLP-1 RC-S is a selective GLP-1 agonist; GLP-1 RC-T is a dual GIP/GLP-1 agonist. This dual mechanism is unique among currently studied peptides and is believed to contribute to glp-1-rc-t's observed efficacy profile in metabolic research.

Molecular Structure

Both peptides use fatty acid modifications to extend their half-lives through albumin binding, but the implementations differ:

Published Research Highlights

GLP-1 RC-S Research

GLP-1 RC-T Research

Which Is Right for Your Research?

The choice depends on the research question:

Both peptides require careful reconstitution and storage to maintain stability. If you are new to handling lyophilised peptides, start with our how-to guide series and use the reconstitution calculator to confirm dosing volumes. Always verify peptide identity and purity by reading the COA before beginning any protocol.

Frequently Asked Questions

What is the main difference between GLP-1 RC-S and GLP-1 RC-T?
GLP-1 RC-S is a selective GLP-1 receptor agonist, while GLP-1 RC-T is a dual GIP/GLP-1 receptor agonist. This means GLP-1 RC-T activates two incretin pathways simultaneously, whereas GLP-1 RC-S targets only one.

How often are GLP-1 RC-S and GLP-1 RC-T administered in research?
Both peptides are designed for once-weekly administration due to their extended half-lives - approximately 7 days for GLP-1 RC-S and approximately 5 days for GLP-1 RC-T.

Which peptide has stronger published metabolic data?
Published SURMOUNT trial data shows GLP-1 RC-T at higher doses produced larger metabolic effects than GLP-1 RC-S, likely due to additional GIP pathway engagement. However, GLP-1 RC-S has more established cardiovascular outcomes data from the SELECT trial.

Continue the conversation

From the Lab - GLP-1 research on LinkedIn & Facebook

Research-Grade Peptides, Lab-Verified

New-U Research Compounds stocks both GLP-1 RC-S and GLP-1 RC-T in 10-vial packs, verified by Janoshik and Freedom Diagnostics.

Shop Now